Ramucirumab Shows Promise in Care of Advanced Gastric Cancer

This article originally appeared here.
Share this content:
Ramucirumab Shows Promise in Care of Advanced Gastric Cancer
Ramucirumab Shows Promise in Care of Advanced Gastric Cancer

TUESDAY, Oct. 24, 2017 (HealthDay News) -- Ramucirumab appears to be safe and effective for the treatment of advanced gastric cancer, according to a study published online Sept. 29 in the Journal of Gastroenterology and Hepatology.

Kei Muro, M.D., from Aichi Cancer Center Hospital in Japan, and colleagues conducted subgroup analyses the REGARD and RAINBOW trials. Both were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma.

The researchers found that the hazard ratios (HRs) for overall survival favored treatment with ramucirumab in the REGARD study: ≤45 years (HR, 0.59; 95 percent confidence interval [CI], 0.27 to 1.26); <65 years (HR, 0.8; 95 percent CI, 0.59 to 1.1); ≥65 years (HR, 0.72; 95 percent CI, 0.48 to 1.08), ≥70 years (HR, 0.73; 95 percent CI, 0.44 to 1.23), and ≥75 years (HR, 0.59; 95 percent CI, 0.25 to 1.37). HRs for overall survival also favored treatment with ramucirumab in the RAINBOW study: ≤45 years (HR, 0.56; 95 percent CI, 0.33 to 0.93), <65 years (HR, 0.78; 95 percent CI, 0.63 to 0.97), ≥65 years (HR, 0.88; 95 percent CI, 0.66 to 1.18), and ≥70 years (HR, 0.88; 95 percent CI, 0.6 to 1.28). The exception was elderly individuals ≥75 years in the RAINBOW trial (HR, 0.97; 95 percent CI, 0.47 to 2.01), through there were only 36 patients in this subgroup. Similar results were seen for progression-free survival. Adverse events, including serious ones, were not associated with age.

"Despite some limitations, these exploratory analyses support the use of ramucirumab in advanced gastric cancer, irrespective of age," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry, including Eli Lilly and Co., which funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »